ZA906927B - Neurotrophin-3,a neutrotrophic factor related to nerve growth and brain derived neurotrophic factor - Google Patents

Neurotrophin-3,a neutrotrophic factor related to nerve growth and brain derived neurotrophic factor

Info

Publication number
ZA906927B
ZA906927B ZA906927A ZA906927A ZA906927B ZA 906927 B ZA906927 B ZA 906927B ZA 906927 A ZA906927 A ZA 906927A ZA 906927 A ZA906927 A ZA 906927A ZA 906927 B ZA906927 B ZA 906927B
Authority
ZA
South Africa
Prior art keywords
neurotrophin
factor
nerve growth
derived neurotrophic
brain derived
Prior art date
Application number
ZA906927A
Other languages
English (en)
Inventor
Andreas Hohn
Hohn Andreas
Joachim Leibrock
Leibrock Joachim
Karen Bailey
Bailey Karen
Yves-Alain Barde
Barde Yves-Alain
Hans Friedrich Erwin Thoenen
Friedrich Erwin Thoenen Hans
Peter C Maisonpierre
C Maisonpierre Peter
Mark E Furth
E Furth Mark
Ronald M Lindsay
M Lindsay Ronald
George Yancopoulos
Yancopoulos George
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of ZA906927B publication Critical patent/ZA906927B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA906927A 1989-08-30 1990-08-30 Neurotrophin-3,a neutrotrophic factor related to nerve growth and brain derived neurotrophic factor ZA906927B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor

Publications (1)

Publication Number Publication Date
ZA906927B true ZA906927B (en) 1991-06-26

Family

ID=23584217

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA906927A ZA906927B (en) 1989-08-30 1990-08-30 Neurotrophin-3,a neutrotrophic factor related to nerve growth and brain derived neurotrophic factor
ZA906926A ZA906926B (en) 1989-08-30 1990-08-30 Brain derived neurotrophic factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA906926A ZA906926B (en) 1989-08-30 1990-08-30 Brain derived neurotrophic factor

Country Status (8)

Country Link
US (2) US5180820A (cs)
JP (1) JP2783450B2 (cs)
CZ (1) CZ285649B6 (cs)
DD (2) DD299197A5 (cs)
GR (1) GR1002052B (cs)
LT (2) LT4011B (cs)
RU (2) RU2131926C1 (cs)
ZA (2) ZA906927B (cs)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
US6780837B1 (en) * 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US6933276B1 (en) 1989-08-30 2005-08-23 Regeneron Pharmaceuticals, Inc. Methods of treating peripheral neuropathies using neurotrophin-3
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
FR2671487B1 (fr) * 1991-01-14 1993-03-19 Oreal Utilisation d'un facteur de croissance dans une composition amincissante.
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
US5175103A (en) * 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
ATE163006T1 (de) * 1993-06-01 1998-02-15 Ono Pharmaceutical Co Pentansäurederivate
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
CA2176216A1 (en) * 1993-11-09 1995-05-18 Virginia M.-Y. Lee Compositions and methods for producing and using homogeneous neuronal cell transplants
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
ATE232089T1 (de) * 1994-11-10 2003-02-15 Univ Kentucky Res Found Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
TR199901734T2 (xx) * 1996-11-15 2000-01-21 Genentech, Inc. N�rotrofinlerin ar�t�lmas�.
AU718500B2 (en) 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6391544B1 (en) * 1998-05-15 2002-05-21 Abbott Laboratories Method for using unequal primer concentrations for generating nucleic acid amplification products
IL141755A0 (en) * 1998-09-04 2002-03-10 Wolfe Res Pty Ltd Medical implant system
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
JP2000169389A (ja) * 1998-12-08 2000-06-20 Sumitomo Pharmaceut Co Ltd 触覚異常治療剤
RU2156621C1 (ru) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
JP2002223748A (ja) * 2001-01-31 2002-08-13 Norio Sakuragawa 網膜神経節細胞培養用培地、眼科用組成物及び網膜神経節細胞保護剤
EP1373905A2 (de) * 2001-04-06 2004-01-02 BioVisioN AG Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
SI2248899T1 (sl) 2003-03-19 2015-07-31 Biogen Ma Inc. Vezavni protein receptorja Nogo
RU2265446C2 (ru) * 2003-05-14 2005-12-10 Григорьянц Рубен Исаакович Имплантат для лечения болезни паркинсона
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
ES2411455T3 (es) * 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
JP2007537145A (ja) * 2003-12-22 2007-12-20 グラクソ　グループ　リミテッド アルツハイマー病の治療のためのｎｏｇｏａ抗体
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US7037698B2 (en) 2004-05-19 2006-05-02 Amano Enzyme Inc. Pyrroloquinoline quinone-dependent glucose dehydrogenase
JP4960865B2 (ja) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄に関連する状態の処置
CA2614421A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
AU2007320311B2 (en) 2006-11-17 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Nerve elongation promoter and elongation inhibitor
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US20100112557A1 (en) * 2008-11-03 2010-05-06 Applied Biosystems Inc. Method for high resolution melt genotyping
US20100112565A1 (en) * 2008-11-03 2010-05-06 Life Technologies Corporation Methods, kits, and reaction mixtures for high resolution melt genotyping
WO2010079850A2 (en) 2009-01-12 2010-07-15 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of cancer
PT2396038E (pt) 2009-02-12 2016-02-19 Curna Inc Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP4273164A3 (en) 2009-10-09 2024-01-24 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
RU2606012C2 (ru) * 2009-11-09 2017-01-10 Дженепод Терапевтикс Аб Новая вирусная векторная конструкция для нейронспецифического оптимизированного непрерывного синтеза dopa in vivo
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9149427B2 (en) 2010-12-02 2015-10-06 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
ES2694592T3 (es) * 2012-03-15 2018-12-21 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
JP6850734B2 (ja) 2015-05-27 2021-03-31 ニューロテック ユーエスエー， インコーポレイテッド 眼の障害の処置のためのカプセル化細胞療法の使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DK161152C (da) * 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
US4680262A (en) * 1984-10-05 1987-07-14 Genentech, Inc. Periplasmic protein recovery
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
IT1219839B (it) * 1988-02-08 1990-05-24 Fidia Farmaceutici Purificazione,caratterizazione e applicazione di un fattore neuronotrofico derivato da cervello di nammifero
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
KR890701605A (ko) * 1987-07-04 1989-12-21 원본미기재 Dna 서열, 재조합 dna 분자 및 용해성 t4 단백질의 제조방법
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
WO1990006764A1 (en) * 1988-12-15 1990-06-28 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
WO1990014363A1 (en) * 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
EP0414151B1 (en) * 1989-08-21 1995-03-15 Takeda Chemical Industries, Ltd. Production of human nerve growth factor proteins
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
AU654302B2 (en) * 1990-09-25 1994-11-03 Genentech Inc. Novel neurothrophic factor
US7020718B2 (en) 2000-05-15 2006-03-28 Hewlett-Packard Development Company, L.P. System and method of aggregating discontiguous address ranges into addresses and masks using a plurality of repeating address blocks

Also Published As

Publication number Publication date
DD299196A5 (de) 1992-04-02
GR900100653A (el) 1991-12-30
LTIP1546A (en) 1995-07-25
US5453361A (en) 1995-09-26
RU2131926C1 (ru) 1999-06-20
LT4063B (en) 1996-11-25
RU2128226C1 (ru) 1999-03-27
LT4011B (en) 1996-08-26
US5180820A (en) 1993-01-19
DD299197A5 (de) 1992-04-02
ZA906926B (en) 1991-06-26
JPH05328974A (ja) 1993-12-14
LTIP1818A (en) 1995-09-25
JP2783450B2 (ja) 1998-08-06
CZ285649B6 (cs) 1999-10-13
CZ422990A3 (cs) 1999-06-16
GR1002052B (en) 1995-11-20

Similar Documents

Publication Publication Date Title
ZA906927B (en) Neurotrophin-3,a neutrotrophic factor related to nerve growth and brain derived neurotrophic factor
GB2231482B (en) Helmet assemblies
KR960008863B1 (en) Rom and process for producing the same
EP0263446A3 (en) Prints and production method thereof
IL92958A (en) Purified human sciatic nerve ciliary neurotrophic factor and methods for the preparation thereof
GR871294B (en) Oven product and preparation method therefor
HUT45055A (en) Process for producing hexahydro-8-hydroxy-2,6-methano-2h-3(4h)-one-esters and their derivatives
EP0410719A3 (en) Colour correction system and method
GB2159520B (en) 1, 24-dihydroxy- 22-vitamin d3 and process for preparing same
PL286433A1 (en) Electrolyzer segment, especially of the filtration press type and a monopolar electrolyzer, especially of the filtration press type
EP0256537A3 (en) Color print and a method for producing the same
GB8921226D0 (en) Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof
DE3760508D1 (en) 1,1-dichloro-1,2,2-trimethyl-2-phenyldisilane and method for producing the same
EP0252391A3 (en) 1,2,2-trimethyl-1-phenyl polydisilane and method for producing the same
GB8629817D0 (en) Producing filaments
EP0413999A3 (en) N,n-bis-1,3,5-triazine-6-yl-piperazines and processes for their preparation
DE3661830D1 (en) 2,4-dichlorothiazole derivatives and process for their preparation
GB2195630B (en) Method for producing carnitine, l-carnitineamide hydrolase and method for producing same
GB2186570B (en) 9,10-dihydro-phenanthrene derivatives and process for their preparation
GB2199827B (en) Novel aminoalkanoyl-dibenzo[d,g][1,3,6]dioxazocines and a process for the preparation thereof
EP0274066A3 (en) Benzothiazolones, and their production and use
GB2198179B (en) Rocker assemblies
EP0313740A3 (en) N-phenyl-2,2,6,6-tetrahalocyclohexaneimine and processes for preparing 2,2,6,6-tetrahalocyclohexaneimine derivative and 2,6-dihaloaniline derivative
EP0258773A3 (en) Benzothiazolones, and their production and use
GB8710307D0 (en) Producing crown wheel cam